When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Essential hypertension

Evidencia revisada por última vez: 21 Jul 2026
Tema actualizado por última vez: 19 Aug 2026

Resumen

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥80 mmHg
  • retinopathy
Todos los datos

Otros factores de diagnóstico

  • headache
  • visual changes
  • dyspnea
  • chest pain
  • sensory or motor deficit
Todos los datos

Factores de riesgo

  • obesity
  • aerobic exercise <3 times/week
  • alcohol intake
  • metabolic syndrome
  • diabetes mellitus
  • black ancestry
  • age >60 years
  • family history of hypertension or chronic coronary disease
  • sleep apnea
  • sodium intake >1.5 g/day
  • low fruit and vegetable intake
  • dyslipidemia
  • smoking
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • urinary albumin-to-creatinine ratio (UACR)
  • ECG
  • fasting metabolic panel with estimated GFR
  • lipid panel
  • urinalysis
  • hemoglobin
  • thyroid-stimulating hormone
Todos los datos

Pruebas diagnósticas que deben considerarse

  • plasma renin activity
  • plasma aldosterone
  • renal duplex ultrasound/MRA renal arteries/CT angiography
  • 24-hour urine pheochromocytoma screen
  • plasma fractionated metanephrines
  • 24-hour urine free cortisol
  • sleep study
  • echocardiography
Todos los datos

Algoritmo de tratamiento

Agudo

without chronic renal disease or cardiovascular disease (CVD)-related comorbidity: stage 1 hypertension and lower CVD risk and without diabetes

without chronic renal disease or cardiovascular disease (CVD)-related comorbidity: higher CVD risk or with diabetes

concomitant chronic coronary disease without congestive heart failure

concomitant heart failure (HF)

concomitant left ventricular hypertrophy without chronic coronary disease

concomitant chronic renal disease without cardiovascular disease

concomitant atrial fibrillation without other comorbidity

En curso

refractory/resistant to optimized triple therapy at any stage

Colaboradores

Autores

Jeffrey Brettler, MD, FASH

Internal Medicine

Regional Hypertension Co-lead, Kaiser Permanente Southern California, Los Angeles

Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA

Divulgaciones

JB declares that he has no competing interests.

Agradecimientos

Dr Jeffrey Brettler would like to gratefully acknowledge Dr Joel Handler, Dr Jonathan N. Bella, Dr Moustapha Atoui, Dr Liran Blum, and Dr Michael A. Spinelli, previous contributors to this topic.

Divulgaciones

JH, JNB, MA, LB, and MAS declare that they have no competing interests.

Revisores por pares

Isla Mackenzie, MBChB, PhD, FRCP

Clinical Senior Lecturer in Clinical Pharmacology and Honorary Consultant Physician

University of Dundee

Dundee

UK

Divulgaciones

IM is an elected member of the British Hypertension Society Executive Committee.

Syed Wamique Yusuf, MRCPI, FACC

Associate Professor

Department of Cardiology

University of Texas MD Anderson Cancer Center

Houston, TX

Divulgaciones

SWY declares that he has no competing interests.

Melvin Lobo, MBChB, PhD, MRCP

Director Barts Blood Pressure Centre of Excellence

NHS Reader in Cardiovascular Medicine

Department of Clinical Pharmacology

William Harvey Heart Centre

London

UK

Divulgaciones

ML is a consultant for ROX Medical. ML receives honorarium from Cardiosonic, St. Jude Medical, and institutional grant/research support from Medtronic.

Agradecimiento de los revisores por pares

Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.

Divulgaciones

Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024 Oct 7;45(38):3912-4018.Texto completo

Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2025 Nov 4;86(18):1567-678.Texto completo  Resumen

Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020 May;36(5):596-624.Texto completo  Resumen

Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.Texto completo  Resumen

Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov 21;386(10008):2059-68.Texto completo  Resumen

Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015 Jun;65(6):1372-407.Texto completo  Resumen

James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.Texto completo  Resumen

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Diferenciales

    • Drug-induced hypertension
    • Chronic kidney disease
    • Renal artery stenosis
    Más Diferenciales
  • Guías de práctica clínica

    • Standards of care in diabetes
    • 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults
    Más Guías de práctica clínica
  • Folletos para el paciente

    Understanding your blood pressure reading

    Más Folletos para el paciente
  • Calculadoras

    2021 race-free CKD-EPI equations for glomerular filtration rate (GFR)

    Glomerular Filtration Rate Estimate by the IDMS-Traceable MDRD Study Equation

    Más Calculadoras
  • Videos

    How to perform an ECG: animated demonstration

    Más vídeos
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad